TCRX – tscan therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TScan Therapeutics (NASDAQ:TCRX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
TScan Therapeutics Announces Positive Updated Data from the ALLOHA™ Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities
TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: Amello Jason
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: MacBeath Gavin
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: Dworak Leiden
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: Louis Chrystal
Form 4 TScan Therapeutics, Inc. For: Jan 20 Filed by: ZDRAVESKI ZORAN
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.